Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 16

1.

Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.

De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE.

J Clin Oncol. 2010 Jan 1;28(1):149-53. doi: 10.1200/JCO.2009.24.1455. Epub 2009 Nov 16.

2.

Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.

Steinberg M.

Clin Ther. 2008 Sep;30(9):1590-617. doi: 10.1016/j.clinthera.2008.09.015. Review.

PMID:
18840366
3.

Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.

Roque DM, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Nelson WK, Santin AD.

Gynecol Oncol. 2015 Jun;137(3):392-400. doi: 10.1016/j.ygyno.2015.03.008. Epub 2015 Mar 17. Review.

PMID:
25792179
4.

Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.

Rivera E, Lee J, Davies A.

Oncologist. 2008 Dec;13(12):1207-23. doi: 10.1634/theoncologist.2008-0143. Epub 2008 Dec 16. Review.

5.

Epothilones in the treatment of ovarian cancer.

Diaz-Padilla I, Oza AM.

Future Oncol. 2011 Apr;7(4):559-68. doi: 10.2217/fon.11.26. Review.

PMID:
21463144
6.

Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.

Yardley DA.

Clin Breast Cancer. 2008 Dec;8(6):487-92. doi: 10.3816/CBC.2008.n.058. Review.

PMID:
19073502
7.

Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance.

Edelman MJ, Shvartsbeyn M.

Clin Lung Cancer. 2012 May;13(3):171-80. doi: 10.1016/j.cllc.2011.02.005. Epub 2011 May 19. Review.

PMID:
22133291
8.

Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.

Trivedi M, Budihardjo I, Loureiro K, Reid TR, Ma JD.

Future Oncol. 2008 Aug;4(4):483-500. doi: 10.2217/14796694.4.4.483. Review.

PMID:
18684060
9.

Epothilones: clinical update and future directions.

Donovan D, Vahdat LT.

Oncology (Williston Park). 2008 Apr 15;22(4):408-16; discussion 416, 421, 424 passim. Review.

10.

Ixabepilone for the treatment of taxane-refractory breast cancer.

Moulder SL.

Future Oncol. 2008 Jun;4(3):333-40. doi: 10.2217/14796694.4.3.333. Review.

PMID:
18518758
11.

Profile and potential of ixabepilone in the treatment of pancreatic cancer.

Smaglo BG, Pishvaian MJ.

Drug Des Devel Ther. 2014 Jul 14;8:923-30. doi: 10.2147/DDDT.S52964. eCollection 2014. Review.

13.

Therapeutic strategies in epithelial ovarian cancer.

Kim A, Ueda Y, Naka T, Enomoto T.

J Exp Clin Cancer Res. 2012 Feb 13;31:14. doi: 10.1186/1756-9966-31-14. Review.

14.

Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.

Marchetti C, Palaia I, De Felice F, Musella A, Donfracesco C, Vertechy L, Romito A, Piacenti I, Musio D, Muzii L, Tombolini V, Benedetti Panici P.

Cancer Treat Rev. 2016 Jan;42:41-6. doi: 10.1016/j.ctrv.2015.10.011. Epub 2015 Nov 10. Review.

PMID:
26559739
15.

Resistance to chemotherapy in ovarian carcinoma.

Lage H, Denkert C.

Recent Results Cancer Res. 2007;176:51-60. Review.

PMID:
17607916
16.

╬▓III-Tubulin: biomarker of taxane resistance or drug target?

Karki R, Mariani M, Andreoli M, He S, Scambia G, Shahabi S, Ferlini C.

Expert Opin Ther Targets. 2013 Apr;17(4):461-72. doi: 10.1517/14728222.2013.766170. Epub 2013 Feb 2. Review.

PMID:
23379899
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk